ascopubs.org25d
KEYMAKER-U03 Substudy 03B: Pembrolizumab (pembro) and targeted therapy combinations for advanced clear cell renal cell carcinoma (ccRCC).
Nivolumab plus cabozantinib (N+C) vs sunitinib (S) for previously untreated advanced renal cell carcinoma (aRCC): Final follow-up results from the CheckMate 9ER trial. Casdatifan (Cas) monotherapy in ...
CNET29d
Best Bug Sprays for 2025
Get outside of the mosquito netting and prevent bug bites with the best bug repellents chosen by our experts. Cookouts, hikes and lounging by the pool might all be on your warm-weather wish list ...
ascopubs.org24d
KEYMAKER-U03 Substudy 03B: Pembrolizumab (pembro) and novel immunotherapy agents for advanced clear cell renal cell carcinoma (ccRCC).
Outcomes of different therapeutic modalities for patients with metachronous oligometastatic renal-cell carcinoma (RCC): Analyses of a single-institution database.
UroToday8d
ASCO GU 2025: KEYMAKER-U03 Substudy 03B: Pembrolizumab and Targeted Therapy Combinations for Advanced Clear Cell Renal Cell Carcinoma (ccRCC)
Dr. Kathryn E. Beckermann presented KEYMAKER-U03 Substudy 03B of pembrolizumab plus targeted therapy combination for advanced clear cell renal cell carcinoma (ccRCC). Despite high response rates, ...